Zona buys BCR 145.94: "IBRUTINIB THREE YEAR FOLLOW-UP OF SINGLE-AGENT AND COMBINATION STUDY RESULTS IN CHRONIC LYMPHOCYTIC LEUKEMIA"
In malignant B cells, there is excessive signalling through the B cell receptor signalling (BCR) pathway, which includes BTK ... May 30, 2014 /PRNewswire/ --Ã AbbVie (NYSE: ABBV) released preliminary results from an ongoing Phase Ibrutinib study with ... ...
40 people liked this
0 Comments:
Post a Comment
Subscribe to Post Comments [Atom]
<< Home